Amarin : JPM Presentation 2023

41st Annual J.P. Morgan Healthcare Conference

Karim Mikhail

President & CEO

January 23

Forward Looking

Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks

of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

Summary

01

The Amarin Journey

Changing the Paradigm in Cardiovascular Care

02

Progress In 2022

Solid Execution Against Ambitious Objectives

03

The Next Chapter

Becoming a Diversified, Global Cardiometabolic Player

04

2023 Key Priorities

Positioned for Successful Execution

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks

of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

The Amarin Journey

Changing the Paradigm in Cardiovascular Care

The Amarin Journey

The Amarin Journey - Changing The Paradigm

Amarin Delivered on Pursuing Cardiovascular Outcomes

2009	2012
Focus on preventative cardiovascular care,	FDA approval
with the start of Amarin's Phase 3 clinical
program MARINE and ANCHOR studies

2018

Publication of REDUCE-IT® study results in New England Journal of Medicine (Nov '18)

2020

Launch of VASCEPA®

in the United States

to reduce cardiovascular risk beyond cholesterol lowering therapy in high-risk patients

PART 1 - TARGETED U.S. COMMERICAL EFFORT FOR NICHE HIGH TRIGLYCERIDES INDICATION

PART 2 - PURSUING CARDIOVASCULAR OUTCOMES & U.S. COMMERCIALIZATION

2011

Start of the landmark cardiovascular outcomes REDUCE-IT® trial

2013

Launch of VASCEPA®

to treat severe (≥500 mg/dL) hypertriglyceridemia, known as very high triglycerides (VHTG)

2019

• FDA approval of Vascepa® to reduce cardiovascular risk
• EMA submission accepted
• Icosapent ethyl in guidelines issued by European Society of Cardiology (ESC) & European Atherosclerosis Society (EAS)

2021

Amarin loses patent protection in the United States

January 23

5